So Merck is plunging ahead in one of medicine's toughest challenges finding a drug to slow Alzheimer's disease despite repeated failures that have led most drugmakers to halt or scale back research on the No. 6 killer in the U.S. It's a particularly risky strategy because scientists are still unraveling exactly what drives Alzheimer's.